Scientific Publications

Westcott N, Boesch A, Rybakin V, Hwang JY, Jørgensen K, Lassen R, Kraemer M, Bak M, Veiga G, Bruun J, Tassa C, Rodts H, Sequeira M, Sauer K, Andresen, TL. Deep TLR Primed™ T cells induce potent anti-tumor activity without systemic toxicity. American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy, November 17–20, 2019.

Geretti E, Sackton K, Cao P, Carey S, Liang X, Nardozzi J, Gui Z, Worthylake A, Hewes B, Maniar T, Fitzgerald J, Rakestraw A, Jones D, Sauer K, Andresen T. Combining Deep IL-12 Primed™ and Deep IL-15 Primed™ T cells induces potent antigen-dependent in vitro cytotoxicity and in vivo anti-tumor activity. American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy, November 17–20, 2019.

Ahmad G, Nardozzi J, Ringgaard L, Christensen E, Jaegher D, Suchy J, Karsten Sauer, Douglas Jones, Andresen T. Adoptive transfer of deep primed™ IL-12 T-cells increases sensitivity to PD-L1 blockade for superior efficacy in checkpoint refractory tumors. Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting, November 6–10, 2019.

Sackton K, Geretti E, Cao P, Carey S, Liang X, Nardozzi J, Gui Z, Worthylake A, Leary G, Hewes B, Maniar T, Fitzgerald J, Rakestraw A, Sauer S, Jones D, Andresen T. Combining Deep™ IL-12 Primed and Deep™ IL-15 Primed T cells leverages complementary mechanisms to enhance anti-tumor activity. Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting, November 6–10, 2019.

Boesch A, Rybakin V, Westcott N, Hwang JY, Jørgensen K, Lassen R, Kraemer M, Bak M, Veiga G, Bruun J, Tassa C, Rodts H, Sequeira M, Leary G, Caruso S, Hewes B, Fitzgerald J, Sauer K, Andresen T. Delivery of TLR7 agonists by Deep-Primed™ T cells induces immune activation and improves anti-tumor activity in mice while circumventing systemic toxicity. Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting, November 6–10, 2019.

Carey SP, McInnis CM, Worthylake A, Forte A, Brown E, Smith D, Sackton K, Soucy R, Maniar T, Sauer K, Rakestraw A, Andresen T. Optimized process for manufacturing Deep-Primed™ T cells creates product with improved functional characteristics and reactivity against multiple tumor-associated antigens. Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting, November 6–10, 2019.

Geretti E, Liang X, Lyons J, Bardwell P, Caruso S, Hewes B, Fitzgerald J, Sauer K, Andresen T. Deep IL-15 primed T cells synergize with PD-L1 blockade to overcome resistance to checkpoint immunotherapy. AACR Annual Meeting 2019, April 1, 2019.

Chang D-K, Ahmad G, Nardozzi J, Sackton K, Lyons J, Sauer K, Andresen T, Jones D. Surface-tethered IL-12 improves tumor-specific T-cell therapy and enhances inflammatory activity in tumors without inducing systemic toxicities. AACR Annual Meeting 2019, March 31, 2019.

Carey SP, Pearce B, Smith D, Cao P, McInnis C, Shaw A, Bruun J, Fachin F, Hewes B, Fitzgerald JB, Andresen TL, Rakestraw A. Deep™ IL-15 Primed multi-targeted T cells demonstrate potent antigen-specific cytotoxic activity against human cancer cells. Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting, November 7–11, 2018.

Chang D-K, Ahmad G, Nardozzi JD, Sackton KL, Andresen TL, Jones DS. Tethering IL-12 to the surface of T cells induces broad immune activation and potent anti-tumor activity in mice without inducing systemic toxicities. Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting, November 7–11, 2018.

Bardwell PD, Geretti E, Liang X, Caruso S, Chang D-K, Lyons J, Tassa C, Bilic S, Lansita J, Hewes B, Fitzgerald J, Andresen TL. Preclinical evaluation of Deep™ IL-15 Primed PMEL cells demonstrates highly improved safety compared to systemic administration of IL-15. Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting, November 7–11, 2018.

McInnis CM, Shaw AM, Carey SP, Bruun J, Klaski R, Cao P, Brown E, Rakestraw A, Hewes B, Fitzgerald J, Andresen TL, Fachin F. A fully closed, high efficiency manufacturing technology platform for the production of T cell therapies targeting multiple tumor antigens. Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting, November 7–11, 2018.

Geretti E, Bardwell P, Liang X, Caruso S, Chang D-K, Lyons J, Boesch A, Handler A, Tassa C, Bilic S, Lansita J, Hewes B, Fitzgerald J, Andresen T. T cell priming with Deep™ IL-15 improves preclinical safety compared to systemic IL-15, and increases in vivo persistence and activity. CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference, September 30, 2018.

Tang L, Zheng Y, Melo MB, Mabardi L, Castaño AP, Xie YQ, Li N, Kudchodkar SB, Wong HC, Jeng EK, Maus MV, Irvine, DJ. Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery. Nat. Biotechnol. (2018) Jul 9. doi: 10.1038/nbt.4181. [Epub ahead of print]

Cao P, Chang D-K, Rakestraw A, Shaw A, Pucci F, Fachin F, McInnis C, Carey S, Boesch A, Chirgwin D, Tassa C, Handler A, Jones K, Bardwell P, Geretti E, Liang X, Nardozzi J, Jones D, Lyons J, Fitzgerald JB, Hewes B, Nielsen UB, Andresen, TL. Deep™ IL-15 provides autocrine stimulation and expansion of autologous T cells driven by controlled concentrated release of IL-15. AACR Annual Meeting 2018, April 17, 2018.

Nardozzi J, Geretti E, Chang D-K, McMillin DW, Lyons J, Nielsen U, Andresen T, Jones D. Cell therapy with surface-tethered IL-12 provides immune system priming and strong anti-tumor activity. AACR Annual Meeting 2018, April 17, 2018.

Fichter M, Tang L, Zheng Y, Melo M, Li N, Irvine D. T cell receptor signaling-responsive single chain IL-12 and IL-15 superagonist nanogel ‘backpacks’ to enhance adoptive cell therapy in solid tumors. AACR Annual Meeting 2018, April 17, 2018.

Jones RB, Mueller S, Kumari S, Vrbanac V, Genel S, Tager AM, Allen TM, Walker BD, Irvine DJ. Antigen recognition-triggered drug delivery mediated by nanocapsule-functionalized cytotoxic T-cells. Biomaterials (2016) 117:44-53.

Stephan MT, Stephan SB, Bak P, Chen J, Irvine DJ. Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles. Biomaterials (2012) 33(23):5776-5787.

Stephan MT, Moon JJ, Um SH, Bershteyn A, Irvine DJ. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat. Med. (2010). 16(9):1035-1041.

Back to Top